Grace Burns

It might be $25 or $7.70 if you've got a concession card.

Yes.

Monjaro is to zapotide, and that is only available privately in Australia at the moment.

And what they tried to do was say, this is a really good drug.

It acts through dual pathways.

It's been shown in some studies to be even better at glucose control in diabetes, be really good at weight management, better than some of the other drugs.

So they tried to say, let's put it on the PBS for people with type 2 diabetes so it's affordable, equity.

Let's make it accessible to people who need it.

So who do, the PBS or the Payback?

And for people, this costs $645 a month, roughly, if you're on the higher dose.

But it can be costly, Norman.

And with this decision, around 450,000 people are going to miss out on the medication with type 2 diabetes.

I mean, I'm thinking from a clinician point of view, oh, it would be a game changer.

It's sad.

There are, but sometimes you don't get the response that you need from that medication and you go, wouldn't it be wonderful to go to the dual action medication for this person?

And it's a big financial hit.

Are they as effective?

Would we know any of them?

Do we know a name?

And it could make the drug company a lot of money.